Clinical trials in rare lymphomas

The table below shows a list of The Lymphoma Group's current clinical trials open for recruitment for rare lymphomas such as:

  • Mantle cell lymphoma
  • Burkitt's lymphoma
  • MALToma (Marginal zone) lymphoma
  • CNS (brain) lymphoma

To find out how you can access one of these clinical trials or to contact us with a question, see our page 'How to be referred'. 

For an explanation on the different phases of trials click here.

 

 

Trial name

 

Description

 

Click for more information (external page)

 

ADCT-402-101

 

A Phase 1 study evaluating the new drug ADCT-402.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

BI 1206 CRUK CD32b

 

Phase 1/2a study looking at blocking the CD32b protein with the antibody BI 1206.

Suitable for patients with various rare lymphoma types which have come back after previous treatment

 

 

 

ENRICH

 

A phase 2/3 trial looking at treatment options for people over 60 with mantle cell lymphoma who are unable to have a stem cell transplant

Suitable for patients with mantle cell lymphoma who haven’t yet received any treatment

 

 

 

GILEAD 1757

 

Phase 1b study of the selective BTK inhibitor ONO/GS-4059.

Suitable for patients with various rare lymphoma types which have come back after previous treatment

 

 

 

IELSG 42

 

Phase 2 trial testing the MARIETTA chemo-immunotherapy regimen followed by high-dose chemotherapy and autologous stem cell transplant.

Suitable for patients with CNS (brain) lymphoma who haven't yet received any treatment.

 

 

 

LYMRIT-37-01 (Betalutin)

 

Phase 1-2 study of the antibody Betalutin® which targets the CD37 antigen.

Suitable for patients with various rare lymphoma types which have come back after previous treatment

 

 

 

MEDI4736 (FUSION)

 

Phase 1-2 study to assess the safety and tolerability of durvalumab, the anti-pd-l1 antibody.

Suitable for patients with mantle cell lymphoma which has come back after previous treatment

 

 

 

TIER

 

Phase 1-2 trial to find the best dose and test the safety and effectiveness of the TIER regimen of chemotherapy and rituximab.

Suitable for patients with CNS (brain) lymphoma which has come back after previous treatment

 

 

 

PQR309-005

 

A phase 2 trial testing a targeted drug, PQR309.

Suitable for patients with CNS (brain) lymphoma which has come back after previous treatment

 

 

 

MCL Biobank

 

Non medicinal (observational) study suitable for patients with a recent diagnosis of mantle cell lymphoma.

 

 

 

*Please note, we update this page fortnightly

With special thanks to the following:

;